The pathophysiology of ADPKD hinges on loss-of-function mutations in PKD1 (chromosome 16p13.3, encoding polycystin-1, 78% of cases) or PKD2 (chromosome 4q21, encoding polycystin-2, 15% of cases). Polycystins form a complex in the primary cilia of renal tubular epithelial cells that regulates intracellular calcium homeostasis and cell proliferation. When this complex is disrupted, intracellular calcium signaling is dysregulated, leading to uncontrolled tubular epithelial cell proliferation and cyst formation along the entire nephron. The structure marked A — innumerable cysts of varying sizes — is the direct morphological consequence of this polycystin dysfunction. This is the foundational molecular mechanism underlying ADPKD and is central to understanding disease pathogenesis and therapeutic targets (e.g., tolvaptan, a V2 receptor antagonist that suppresses cAMP-mediated proliferation).
KDIGO 2024 ADPKD Conference Update
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.